Q&A: Using Ultrasound-Activated Microbubbles to Deliver PROTACs into Cancer Cells Q&A with Yuqi Wu on SonoPIN, an ultrasound-based platform improving targeted #PROTAC delivery and intracellular #proteindegradation in cancer cells @DukeU #ultrasound hubs.li/Q0487mvs0

PROTAC degraders recruiting MDM2 scienceopen.com/hosted-documen… #PROTAC #MDM2 #E3Ligase #TargetedDegradation #DrugDesign

MDM2-BCL-XL PROTACs scienceopen.com/hosted-documen… #PROTAC #MDM2 #BCLXL #Apoptosis #ProteinDegradation

Multi-specific antiviral PROTAC modality scienceopen.com/hosted-documen… #PROTAC #Antiviral #TargetedDegradation #DrugDiscovery #ChemicalBiology

PROTACs targeting epigenetic proteins scienceopen.com/hosted-documen… #PROTAC #Epigenetics #EpigeneticTargets #ProteinDegradation #CancerResearch

PROTAC technology for prostate cancer treatment scienceopen.com/hosted-documen… #PROTAC #ProstateCancer #TargetedTherapy #ProteinDegradation #Oncology

Application of PROTACs in target identification and validation scienceopen.com/hosted-documen… #PROTAC #TargetIdentification #TargetValidation #DrugDiscovery #ChemicalBiology

PROTACs improve selectivity for targeted proteins scienceopen.com/hosted-documen… #PROTAC #ProteinSelectivity #TargetedDegradation #DrugDesign #ChemicalBiology

Advancing PROTACs & Targeted Protein Degradation from Acta Materia Medica Explore the latest research: amm-journal.org #PROTAC #TargetedProteinDegradation #DrugDiscovery #ChemicalBiology

バイオテクは黄金期。PROTAC（標的タンパク質分解薬）など誘導近接型分子と組織特異的DDS（薬を届ける技術）が「創薬困難標的」を攻略。AI過信は禁物、変曲点の見極めが投資の鍵。Booth氏が30年を総括。 doi.org/10.1038/s41587… #PROTAC #DDS #バイオテク投資

#NEWS: Arvinas announces Positive Phase 1 data for its #PROTAC LRRK2 Degrader presented at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026). Learn more here: bit.ly/4rJcqMH

Computational strategies accelerating PROTAC discovery—driving next-generation targeted therapeutics scienceopen.com/hosted-documen… #PROTAC #DrugDiscovery #ComputationalChemistry #TargetedDegradation

We’re looking forward to @adpdnet 2026 this week where we will share data in an oral presentation related to our #PROTAC LRRK2 degrader. Learn more: bit.ly/3MPFELg #ADPD

🐪Hump Day Hack | Enter the Multiverse Just another normal day in the lab… One small mistake—and suddenly I’m pulled into the multiverse. 🌌#PROTAC Dimension: Not inhibition—degradation. 🌌#Inhibitor Zone: Blocking the signal. Pathway controlled. 🌌#Protein Domain: Structuy. ��#ADC Realm: Precision delivery. Target locked. One blink later—back in the lab. Did I just travel through the multiverse? 🧪 #HumpDayHack #ProteinMultiverse #LabLife #LabHumor #LifeScience #ProteinScience #SmallMolecule #BenchLife

🐪Hump Day Hack | Enter the Multiverse Just another normal day in the lab…One small mistake—and suddenly I’m pulled into the multiverse. 🌌#PROTAC Dimension🌌#Inhibitor Zone🌌#Protein Domain��#ADC Realm One blink later—back in the lab. Did I just travel through the multiveRqSSJ

Discover cutting-edge tools for targeted protein degradation with Pharmaron’s custom cell lines and assays. Explore our 8+ years of experience in protein degrader discovery! #TPD #PROTAC #DrugDiscovery #Proteindegraders

RESEARCH PAPER: Combinatorial use of VHL and KEAP1 PROTACs reveals unexpected synergy and hook effect relief By Islam et al., and Luca Busino ➡️ genesdev.cshlp.org/content/40/5-6… @businolab @PennMedicine #PROTAC #KRAS #cancer #cancertherapy

🧬 Sharing a review that highlights how chemoinformatics, molecular modeling, structural bioinformatics, and machine learning are accelerating the design of protein degraders. #openaccess doi.org/10.1016/j.drud…s #PROTAC #DrugDiscovery #Chemoinformatics #CompChem1

��#AZD9750 (Ex.14) is a #PROTAC degrader targeting the androgen receptor with a DC50 of 6 nM. AZD9750 is used in #prostate #cancerresearch. Structure Note: Pink: target protein ligand (HY-175654); Blue: E3 ligase ligand (HY-175654); Black: linker.medchemexpress.com/protac-androge…ZL

We’re at the @AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics this week. We look forward to presenting preclinical data for our #PROTAC pan-KRAS degrader in a poster and short oral session. Learn more about the meeting: bit.ly/4kJbVjF #AACRRAS